Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Sitravatinib Adjuvant Therapy in HCC
NCT05407519Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, sitravatinib in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of USTC. Started Jul 2022; status: recruiting.
02
Drugs
tislelizumabsitravatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05407519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407519.